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α-Conotoxins exhibiting analgesic activity, such as Vc1.1, have been shown to inhibit α9α10 nicotinic
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CaV2.2 channels via GABABR activation but exhibit reduced inhibitory activity at α9α10 and other neuronal
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constriction injury models. Vc1.1[N9R] and benzoyl-Vc1.1[N9R] exhibited either similar or tenfold higher
activity of GABABR-mediated CaV2.2 inhibition but no activity at CaV2.2 alone; however, the mechanism of
increased analgesic activity is unknown. The effects on analgesic activity and α9α10 nAChR of other Vc1.1
variations at position 9 and the N-terminus were also determined. Our findings provide new insights for
designing potent inhibitors for GABABR-coupled N-type (CaV2.2) calcium channels.
Disciplines
Medicine and Health Sciences
Publication Details
Cai, F., Xu, N., Liu, Z., Ding, R., Yu, S., Dong, M., Wang, S., Shen, J., Tae, H., Adams, D. J.., Zhang, X. & Dai, Q.
(2018). Targeting of N-Type Calcium Channels via GABAB-Receptor Activation by α-Conotoxin Vc1.1
Variants Displaying Improved Analgesic Activity. Journal of Medicinal Chemistry, 61 (22), 10198-10205.
Authors
Fengtao Cai, Ning Xu, Zhuguo Liu, Rong Ding, Shuo Yu, Mingxin Dong, Shuo Wang, Jintao Shen, Han Shen
Tae, David J. Adams, Xuerong Zhang, and Qiuyun Dai
This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1318
 1 
Targeting of N-type Calcium Channels via GABAB Receptor 
activation by α-Conotoxin Vc1.1 Variants Displaying Improved 
Analgesic Activity 
 
Fengtao Cai,†,‡ Ning Xu,† Zhuguo Liu,† Rong Ding,† Shuo Yu,† Mingxin 
Dong,† Shuo Wang,† Jintao Shen,† Han-Shen Tae,§ David J. Adams,§,* 
Xuerong Zhang‡,*, Qiuyun Dai*,† 
 
† Beijing Institute of Biotechnology; Beijing 100071, China 
‡ School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, 
China 
§ Illawarra Health and Medical Research Institute (IHMRI), University of 
Wollongong, Wollongong, NSW 2522, Australia 
 
Fengtao Cai, Ning Xu, and Zhuguo Liu contributed equally to this work.  
 
 2 
ABSTRACT: α-Conotoxins exhibiting analgesic activity have been shown to inhibit α9α10 
nicotinic acetylcholine receptors (nAChRs) and GABAB receptor (GABABR)-coupled 
N-type (CaV2.2) calcium channels. Here, we report two Vc1.1 variants, Vc1.1[N9R] and 
benzoyl-Vc1.1[N9R], selectively inhibit CaV2.2 channels via GABABR activation but 
exhibit reduced inhibitory activity at α9α10 and other neuronal nAChR subtypes compared 
to Vc1.1. Surprisingly, the analgesic activity of Vc1.1[N9R] and benzoyl-Vc1.1[N9R] was 
more potent than Vc1.1 when tested in the partial sciatic nerve injury and chronic 
constriction injury models. Vc1.1[N9R] and benzoyl-Vc1.1[N9R] exhibited either similar or 
ten-fold higher activity of GABABR-mediated CaV2.2 inhibition but no activity at CaV2.2 
alone, however, the mechanism of increased analgesic activity is unknown. The effects of 
other Vc1.1 variants at position 9 and the N-terminus were also determined on analgesic 
activity and α9α10 nAChR. Our findings provide new insights to design potent inhibitors 
for GABABR-coupled N-type (CaV2.2) calcium channels. 
 
■ INTRODUCTION  
Nicotinic acetylcholine receptors (nAChRs) are a diverse family of ligand-gated cation 
selective channels which are widely distributed in the central and peripheral nervous 
systems.1, 2 Some nervous system diseases are involved with nAChR dysfunctions,3,4 such as 
neuropathic pain,5~7 Parkinson’s disease,8, 9 and schizophrenia.10 Recently, several nAChR 
subtypes have been identified as potential targets for treatment of neuropathic pain with 
α-conotoxins.11-13 A number of α-conotoxins, such as Vc1.1,14 Rg1A,15 MII,16 and AuIB,17 
which are composed of 11-20 amino acids and two disulfide bridges and target α9α10, α3β2 
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or α3β4 nAChRs, have been shown to possess analgesic activity. 
Vc1.1 is the first α-conotoxin to exhibit potent analgesic activity and accelerate the 
functional recovery of injured neurons,14 and it entered phase II of clinical studies.18 Vc1.1 
reversibly inhibits α9α10 nAChR and weakly inhibits α3β2 and α3β4 nAChRs.19, 20 Vc1.1 
also potently inhibits N-type (CaV2.2) Ca2+ channels via GABABR activation.21 The 
co-administration of a selective GABABR antagonist with Vc1.1 in rats completely abolishes 
its analgesic action, suggesting that the analgesic activity of Vc1.1 is mediated by GABABR 
activation. However, to date, α-conotoxins which exhibit potent analgesic activity are largely 
inhibitors of α9α10 nAChR and GABABR-coupled CaV2.2 channels.22, 23  
In the primary screening of analgesic activity of Vc1.1 variants, the modifications at 
position 9 affected Vc1.1’s analgesic activity, and the substitution of Asn9 with Arg 
improved the analgesic activity of Vc1.1 in rat partial sciatic nerve injury (PNL). Therefore, 
in the present study, we investigated the effects of charge and hydrophobic features at 
N-terminal and position 11 on the analgesic activity of Vc1.1[N9R]. The structure-activity 
relationship of these variants on α9α10 nAChR and GABABR-coupled CaV2.2 channels were 
determined. The results showed that benzoyl-Vc1.1[N9R] apparently improved analgesic 
activities as Vc1.1[N9R] in rat PNL and chronic constriction injury model (CCI) compared to 
Vc1.1, whereas their inhibitory activity at α9α10 nAChR were 29- and 172-fold lower than 
that of Vc.1. In contrast, the two Vc1.1 variants displayed similar or ten-fold higher 
inhibitory activity at CaV2.2 channels in HEK293T cells co-expressed with GABABR but not 
CaV2.2 alone. The results demonstrate that the target specificity of two Vc1.1 variants is 
significantly different from that of Vc1.1. However, the further replacement of Asp11 by Asn 
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or acetylation at the N-terminus of Vc1.1[N9R] significantly reduced the inhibitory activity at 
the rat α9α10 nAChR and GABABR-coupled CaV2.2. These findings provide new insights 
into designing potent inhibitors for GABABR-coupled CaV2.2 channels.  
■ RESULTS 
Chemical Synthesis and Characterization of Vc1.1 Variants. Linear Vc1.1 and its 
variants (Table 1) were folded individually in NH4HCO3 buffer and analyzed by HPLC. The 
typical folding results of Vc1.1[N9R] and benzoyl-Vc1.1[N9R] are shown in Figure 1, other 
Vc1.1 variants are shown in Figures S8-S16; all linear Vc1.1 and its variants folded to form a 
major product. The resulting peptides were further purified and assessed with analytical 
reversed-phase HPLC, and the purity of the peptides was determined as ≥ 95% (Figure 
S8-S16). The mass spectral analysis showed that Vc1.1 and variants were the correct folded 
products (Figure S17-S25). The circular dichroism (CD) spectra of Vc1.1 and its variants in 
0.01 M phosphate buffer showed some ellipticities around 208 nm and 220 nm (Figure 
S26-S34). These results are consistent with previous reports that α4/7-conotoxins have a 
short helical structure if they have the disulfide bridges C1-C3, C2-C4 and a conserved proline 
residue exists in loop 2.12,19 Thus, this structural feature was used to confirm the disulfide 
bridges of Vc1.1 variants.  
Effect of Residues at Position 9 and 11 on the Analgesic Activity of Vc1.1. The 
analgesic activity of Vc1.1 and its variants at position 9 and 11 was assessed using rat PNL 
and CCI models. In the PNL model, ipsilateral Vc1.1[N9R] injection (0.3, 1.5 and 15 
nmol/kg) increased the pain threshold elevation percentages by 16.7 ± 10.0% , 47.2 ± 17.8% 
and 85.0 ± 30.0% (n = 8), respectively, in a dose-dependent manner (Figure 2A), and was 
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higher than Vc1.1 at the same dose, which increased the pain threshold elevation percentages 
by 12.2 ± 14.4%, 25.6 ± 19.4% and 51.1 ± 21.1% (n = 8), respectively. The same tendency 
was observed in rat CCI model (Figure 2B). Next, the analgesic effect of residues at position 
11 on Vc1.1[N9R] was assessed. The replacement of Asp at position 11 with Arg, Ser or Asn 
led to decreased analgesic activity in Vc1.1[N9R, D11R], Vc1.1[N9R, D11S] and Vc1.1[N9R, 
D11N], in which the pain threshold elevation percentages were 35.3 ± 20.0%, 9.0 ± 22.5% 
and 40.8 ± 21.5% (n = 8), respectively (Figure S1), whereas the value for Vc1.1 and 
Vc1.1[N9R] was 58.8 ± 17.5% and 83.8 ± 29.5% (n = 8), respectively, in the same 
experiment. These results demonstrate that the residue at position 11 is also important for the 
analgesic properties of Vc1.1[N9R]. 
Effect of N-terminal Modification on Vc1.1[N9R] Analgesic Activity. The 
N-terminus of Vc1.1[N9R] was further modified with benzoyl, acetyl or other amino acids, 
and the analgesic activity was determined in PNL and CCI rats. When benzoyl was 
introduced to the N-terminal of Vc1.1[N9R], the analgesic activity remained higher than that 
of unmodified Vc1.1 (Figure 3). At a dose of 15 nmol/kg, benzoyl-Vc1.1[N9R] increased the 
pain threshold to 80.0 ± 17.3%, approximately 72% higher than Vc1.1 (46.4 ± 10.0%) 
(Figure 3A). A similar effect was observed in CCI model rats (Figure 3B). N-terminal acetyl 
(Ac) modification or Gly deletion (Des-Gly) from the N-terminus of Vc1.1[N9R] both 
negatively affected analgesic activity, although the activities of these modified peptides were 
comparable with Vc1.1 in PNL rats (Figure S2). 
Potency of Vc1.1 Variants at nAChR Subtypes. Two-electrode voltage clamp was 
used to assess the effects of Vc1.1 variants on ACh-evoked currents of nAChR subunits 
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expressed in Xenopus laevis oocytes. The inhibitory activity of Vc1.1 and several variants at 
rat and human α9α10 nAChRs is shown in Figure 4 and Figure S3, respectively. The IC50 
obtained for inhibition of rat α9α10 nAChR by Vc1.1, Vc1.1[N9R] and benzoyl-Vc1.1[N9R] 
was 28.3 nM, 4901 nM, and 875 nM, respectively (Table 1). The replacement of Asn9 by Arg 
and its further benzoylation at N-terminus resulted in a 29- and 172-fold reduction, 
respectively, in the inhibitory activity of the peptide at rat α9α10 nAChRs. The IC50’s 
obtained for inhibition of human α9α10 nAChR by Vc1.1[N9R], benzoyl-Vc1.1[N9R] and 
benzoyl-Vc1.1 were 363 nM, 5.93 µM, and 12.50 µM, respectively (Table 1). 
Furthermore, the inhibition of rat α3β2, α3β4, α2β4, α2β2, α4β2 and α7 by 10 µM 
Vc1.1[N9R] and benzoyl-Vc1.1[N9R] was reduced by ≥ 50% (Figure S4-S5). These results 
indicate that the analgesic activity of Vc1.1[N9R] and benzoyl-Vc1.1[N9R] is unlikely to be 
due its inhibitory activity at α9α10 or other neuronal nAChR subtypes. Similarly, the 
replacement of Asn9 with Asp, the acetylation of [N9R]Vc.1 at N-terminus and the 
substitution of Asn9 and Asp11 with Arg and Asn, respectively, led to significant decrease in 
the potency of Vc1.1 at rat α9α10 nAChR (Figure 4B). At human α9α10, Vc1.1[N9R] was ~3 
times more potent than Vc1.1 (IC50 = 1 µM)24 (Table 1) . 
Potency of Vc1.1 Variants at GABABR-coupled CaV2.2 Channels. The inhibitory 
activity of Vc1.1 variants on CaV2.2 channels in HEK293T cells co-expressed with GABABR 
was also investigated. Vc1.1[N9R] and benzoyl-Vc1.1[N9R] inhibited CaV2.2 channels via 
GABABR activation to similar degree or greater with an IC50s of 4.9 nM and 0.2 nM, 
respectively, compared to 2.4 nM for Vc1.1 (Figure 5F). The effects of the three peptides 
were antagonized in the presence of 1 µM CGP55845 (n = 4), a selective GABABR 
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antagonist, and a representative effect of benzoyl-Vc1.1[N9R] on HEK293T cells 
coexpressing GABABR and CaV2.2 is shown in Figure 5E. In addition, benzoyl-Vc1.1[N9R] 
was inactive in HEK293T cells expressing CaV2.2 alone (Figure 5E). However, further 
substitutions of Asp with Asn, Ser and Arg or acetylation or deletion of first amino acid at 
N-terminal resulted in a decrease in inhibitory activity (Figure 5H-5G). Similar to 
benzoyl-Vc1.1[N9R], single modifications of benzoylation at the N-terminal led to an 
increase in potency (Figure 5H). Furthermore, the three peptides, Vc1.1, Vc1.1[N9R] and 
benzoyl-Vc1.1[N9R], tested at a concentration of 10 µM had no significant effect on either 
TTX-resistant (TTX-R; Figure S6) or TTX-sensitive sodium channels (TTX-S; Figure S7) in 
rat DRG neurons. These results suggest that Vc1.1[N9R] and benzoyl-Vc1.1[N9R] 
specifically inhibit GABABR-coupled CaV2.2 channels. 
■ DISCUSSION 
According to the residue numbers of the inter cysteine loops (-CC-(loop1)-C-(loop2)-C-), 
α-conotoxins are divided into several subfamilies (α3/5, α4/3, α4/4, α4/6, α4/7 and α5/5).12 
ImI and Rg1A belong to the α4/3 subfamily, whereas PnIA, PnIB and Vc1.1 belong to the 
α4/7 subfamily. Mutagenesis studies of α-conotoxins ImI, Rg1A, PnIA, PnIB and Vc1.1 have 
shown that loop 1 of α-conotoxin plays a key role in recognizing nAChR subtypes and that 
loop 2 is important to both activity and selectivity.25-32 Mutations of Asp5-Arg7 and 
Asp11-Ile15 in Vc1.1 resulted in loss of activity at rat α9α10 nAChR.33 However, replacing 
the polar residue Asn9 with a hydrophobic residue such as Leu, Ile, Phe or Trp significantly 
increased the potency of Vc1.1 at both the rat α9α10 and the human/rat α9α10 hybrid 
nAChRs.32-35 In the present study, substitution of Asn9 with Arg in Vc1.1, the further 
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replacement of Asp11 by Asn or acetylation at the N-terminus of Vc1.1[N9R] significantly 
reduced the inhibitory activity at the rat α9α10 nAChR, which is consistent with a previous 
report that substitution of Asn9 with Lys reduced Vc1.1 activity.34 
Surprisingly, the substitution of Asn9 with Arg in Vc1.1 and further benzoylation at the 
N-terminus apparently increased analgesic activity (Figure 2-3). These results suggest that the 
analgesic activity of Vc1.1[N9R], benzoyl-Vc1.1[N9R] is not due to their reduced inhibitory 
activity at α9α10 nAChR. Similar examples are found in Vc1.1 post-translationally modified 
analogues, such as Vc1a, Vc1.1[P6O] and Vc1.1[E14γ],32 which are equipotent at inhibiting 
α9α10 nAChR but lack analgesic activity in vivo.  
It has been reported that α-contoxins Vc1.1,21 Rg1A,15, 36 PeIA,37 AuIB17 and Vc1.238 
also inhibit GABABR-coupled N-type (CaV2.2) calcium channels. The discrepancy between 
the inhibitory activity of Vc1.1[N9R] and benzoyl-Vc1.1[N9R] at α9α10 nAChR and 
analgesic activity led to the demonstration of their potent inhibition of GABABR-coupled 
CaV2.2 channels in HEK293T cells. Our results showed that Vc1.1[N9R] exhibited similar 
inhibitory activity at GABABR-coupled Cav2.2 channels as Vc1.1 whereas benzoyl-Vc1.1 
and benzoyl-Vc1.1[N9R] are 1- and 10-fold more potent than Vc1.1 (Figure 5). To our 
knowledge, benzoyl-Vc1.1[N9R] is the most potent inhibitor of GABABR-coupled CaV2.2 
channels. In addition, Vc1.1 and the two variants (10 µM) exhibited no significant effect on 
CaV2.2 expressed alone in HEK293T cells, nor TTX-R (Figure S6) and TTX-S Na+ channels 
(Figure S7) in rat DRG neurons. The effect of benzoyl-Vc1.1[N9R] was antagonized in the 
presence of the selective GABAB receptor antagonist, CGP55845. However, the analgesic 
activity of Vc1.1 and Vc1.1[N9R] is not strictly coupled to its potency at GABABR/CaV2.2 
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channels. The in vitro degradation of two peptides (data not shown) appears to exclude the 
possible effects of pharmacokinetics in vivo, but the mechanism of increased analgesic 
activity is unknown.  
In conclusion, the substitution of Asn9 with Arg, or the further modification of the 
N-terminus with a benzoyl group improves Vc1.1 analgesic activity. Our findings will be 
valuable for designing new potent inhibitors for GABABR-coupled CaV2.2 channels. 
 
■ EXPERIMENTAL SECTION 
Animals. Adult male Sprague-Dawley rats (SD, 200-220 g, 6-7 week old) (Beijing 
Animal Center, China) were housed in groups of eight on a 12 h light-dark cycle (light cycle 
from 8 AM – 8 PM) at a temperature of 23 ± 2 °C and a relative humidity of 50%. Food 
pellets and water were available ad libitum. All experiments were conducted in accordance 
with the guidelines of the Beijing Institutes for Biological Sciences Animal Research 
Advisory Committee and conformed to the European Community directives for the care and 
use of laboratory animals. 
Reagents. N-Fmoc-amino acids, HOBt, HBTU, DIEA and TFA were purchased from GL 
Biochem Ltd. (Shanghai, China). Wang resin and Rink resin were obtained from Tianjin 
Nankai Hecheng S&T Co. (China). DTT was obtained from Promega. Baclofen and GABA 
were purchased from Aladdin Reagent (Shanghai, China). All other reagents were of 
analytical grade. Human GABAB1R and GABAB2R subunit cDNA clones were obtained from 
OriGene Technologies, Inc. (Rockville, MD, USA). The rat CaV2.2 channel α1B splice variant 
e37a, and auxiliary subunits β3 and α2δ1 were obtained from Addgene (Cambridge, MA, 
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USA). 
Peptide Synthesis and Folding. Vc1.1 and its variants (Table 1) were synthesized 
using the solid-phase method on an ABI 433A peptide synthesizer (Thermo Fisher Scientific) 
using standard Fmoc chemistry and side-chain protection as described previously.39,40 The 
lyophilized crude linear peptide was folded in 0.1M NH4HCO3 buffer (pH 8.2~8.4) at 
concentration of 0.3 mg/mL in an open flask for 38 h. 
Following oxidation of the peptide, the reaction mixture was acidified (pH < 4.5) with 
acetic acid and loaded on a Nucleosil 25×250 mm preparative C18 column using a 
preparative HPLC pump (Waters Delta Prep 4000). The column was washed with 95% 
acetonitrile containing 0.1% TFA at a flow rate of 5.0 mL/min. The resulting peptide was 
further purified by semi-preparative reversed-phase HPLC using a 10×250 mm Kromasil C18 
column. The purity of the peptide was assessed by analytical reversed-phase HPLC using a 
Calesil C18 column (5 µm, 100 Ǻ, 4.6×250 mm) with a 25 min linear gradient of 8-40% 
buffer B (0.1% TFA in acetonitrile) at a flow rate of 1 mL/min. The purity of all final 
products was of ≥ 95% . Confirmation that the product was of the correct molecular mass was 
obtained by mass spectrometry on a ProFLEXTM-III MALDI-TOF spectrometer. 
Circular Dichroism (CD) Spectra. CD spectra of Vc1.1 and its variants were measured 
between 190 and 340 nm on Chirascan-plus CD (Applied Photophysics ltd., Leatherhead, 
UK). The peptide was dissolved in 0.01 M phosphate buffer (pH 7.2) to a final concentration 
of 35 µM. A 1-mm path length quartz cell was employed. Each spectrum represented the 
accumulation of three individual scans collected at 1.0 nm intervals at a bandwidth of 1.0 nm. 
Analgesic Activity Test. Under pentobarbital (48 mg/kg) anesthesia, partial sciatic 
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nerve injury (PNL) was established according to the method of Seltzer41,42 and chronic 
constriction injury model (CCI) was achieved using the CCI model of Bennett and Xie.43,44 
All behavioral testing was performed seven days after surgery. A successful PNL model was 
defined by a 30-50% decrease in mechanical paw withdrawal thresholds (PWT) for the 
ipsilateral hind paw. Mechanical paw withdrawal thresholds were assessed using an Ugo 
Basile Analgesy-Meter (Ugo Basile, Italy). 
For pharmacological testing, all drugs were dissolved in sterile 0.9% saline. The 
qualified PNL rats and CCI rats (a 30-50% decrease in PWT) were randomly divided into 
peptide groups and a saline group with 8 animals in each group. Saline or Vc1.1 (0.3, 1.5 and 
15 nmol/kg or single dose) or Vc1.1 variants (0.3, 1.5 and 15 nmol/kg or single dose) was 
administered ipsilaterally close to the injury site at a mid-thigh region of mice in a volume of 
200 μL. The number of groups including a saline and Vc1.1 control group in each experiment 
was no more than 7. Paw withdrawal thresholds were measured at 2-2.5 h following 
intramuscular administration. Data are expressed as mean pain threshold elevation 
percentages (PTEPs) ± SD (%PTEP = (Post-drug PWT-Pre-drug PWT)/ Pre-drug PWT×100). 
The unpaired t test was performed, and a p value of < 0.05 was considered statistically 
significant. 
Two-electrode Voltage Clamp. cRNA preparation, oocyte harvesting and expression 
of nAChR subunits and oocyte electrophysiology were performed as described previously. 
38,39 Briefly, the Xenopus laevis oocytes were incubated in ND96 solution (96.0 mM NaCl, 
2.0 mM KCl, 1.8 mM CaCl2, 1.0 mM MgCl2 and 5 mM HEPES, pH ~ 7.3) containing 2.5 
mM pyruvic acid sodium (Sigma, St. Louis, MO, USA) and antibiotics (100 U/mL penicillin, 
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100 mg/mL streptomycin, Sigma) at 18°C. Oocyte recordings were performed 2-4 days 
post-injection at room temperature (~ 22°C). The oocyte was perfused with peptide solution 
until equilibrated (5-10 min). At high concentrations (1 µM or greater), 5.5 µL of a 10-fold 
concentrated peptide solution was directly pipetted into static bath 5 min prior to the exposure 
of ACh pulses. The concentration-response relationships were fit to the equation: % response 
= 100/[1 + ([toxin]/IC50)n], where n is the Hill coefficient and IC50 is the antagonist 
concentration giving half-maximal response, by non-linear regression analysis using 
GraphPad Prism (GraphPad Software, San Diego, CA, USA). 
HEK293T Cell Electrophysiology. HEK293T cells were seeded into 12 well plates and 
transiently cotransfected with human GABAB1 and GABAB2 subunits (2 μg each) and 0.2 μg 
mCherry fluorescent protein using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. After 24 hours, the cells were then transiently cotransfected with rat 
CaV2.2 channels (α1B, β3, and α2δ1 subunits with 1 μg each) and 0.2 μg of the enhanced 
green fluorescent protein using Lipofectamine 2000 as well. 
Two to three days after transfection, cells were seeded on glass coverslips pretreated 
with poly-L-lysine and incubated at 37°C in 5% CO2 for at least 6 hours before recording. 
Whole-cell patch clamp recording from transfected HEK293T cells was performed as 
described previously.23, 37 Briefly, HEK293T cells were superfused with a solution containing 
(in mM): 90 NaCl, 10 BaCl2, 5 CsCl, 30 TEA-Cl, 1 MgCl2, 10 D-glucose, and 10 HEPES, pH 
7.4 with TEA-OH. Fire-polished borosilicate patch pipettes (2–3 MΩ tip resistance) were 
filled with a solution containing (in mM): 120 K-gluconate, 5 NaCl, 2 MgCl2, 5 EGTA, 2 
MgATP, 0.6 Na2GTP, and 10 HEPES, pH 7.2 with CsOH. Whole-cell patch clamp recordings 
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were performed at room temperature (23–25°C) using a MultiClamp 700B amplifier 
(Molecular Devices) controlled by Clampex 10.3/DigiData 1440A acquisition systems. 
Membrane currents were filtered at 2 kHz and sampled at 10 kHz. Leak and capacitive 
currents were subtracted using a −P/4 pulse protocol. Peak current amplitude in response to 
the depolarizing pulse was measured once a steady state was achieved (3–5 minutes). All 
drugs were diluted to the appropriate final concentration and applied via perfusion. Baclofen 
was used as a positive control for functional expression of GABABR with CaV2.2 channels 
and cells responding to baclofen with ≥ 50% peak current inhibition were included in our 
analysis. The concentration-response data were fit to the equation: Y=Ymin + (Ymin - 
Ymax)/(1+10 (Log IC50-X)×h)), where Y is I/I0, h is the Hill coefficient (slope), IC50 is the 
half-maximal inhibitory concentration. The non-linear regression analysis was performed 
using GraphPad Prism (GraphPad Software, San Diego, CA, USA). 
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Table 1. Amino acid sequences of Vc1.1 and analogues and inhibitory activity at α9α10 nAChR and GABABR-coupled CaV2.2 channels  
Peptide      Sequence IC50 (nM, α9α10)#  




Ratio of IC50’s 
in α9α10 vs 
Cav2.2 
Rat PNL model pain 
threshold elevation (%) at 
15 nmol/kg## 
Vc1.1 GCCSDPRCNYDHPEIC* 28.3 (20.8~38.5) (r) 
1000 (h)24  
2.4 (0.8~7.0) 11.8 (r) 
416.7 (h) 
51.1±21.1 
Vc1.1[N9R] GCCSDPRCRYDHPEIC* 4901 (1729~13891) (r) 
363 (306~427) (h) 
4.9 (2.6~9.1) 1000 (r) 
74.1 (h) 
85.0±30.0 
Vc1.1[N9R,D11N] GCCSDPRCRYNHPEIC* 13946 (8204~23707) (r) >1000 <13.9 (r) 40.8±21.5 
Vc1.1[N9R,D11S] GCCSDPRCRYSHPEIC* ND 18.6 (6.3~55.1)  9.0±22.5 
Vc1.1[N9R,D11R] GCCSDPRCRYRHPEIC* ND >1000  35.3±20.0 
Benzoyl-Vc1.1[N9R] Benzoyl-GCCSDPRCRYDHPEIC* 875 (511~1500) (r) 
5929 (4519~8492) (h) 
0.2 (0.1~0.3) 4375 (r) 
>25000 (h) 
80.0±17.3 
Ac-Vc1.1[N9R] Ac-GCCSDPRCRYDHPEIC* 2416 (1462~3993) (r) 18.9 (7.9~45.5) 127.8 (r) 24.8±10.0 
∆-Gly-Vc1.1[N9R] CCSDPRCRYDHPEIC* ND 23.2 (11.1~48.6)  32.5±10.6 
Benzoyl-Vc1.1 Benzoyl-GCCSDPRCNYDHPEIC* 12503 (8417~28510) (h) 1.2 (0.2~5.6) >10000 (h)  
*C-terminus is amidated. The mutated residues are shown by bold and italic typeface. #Numbers in parentheses indicate 95% confidence intervals, n = 4-6. ##Data are expressed as mean ± SD.
Figure Legends 
 
Figure 1. HPLC analysis of the folding of typical Vc1.1 variants. (a) Vc1.1[N9R] linear 
peptide and (b) Vc1.1[N9R] folded products, (c) Benzoyl-Vc1.1[N9R] linear peptide and (d) 
Benzoyl-Vc1.1[N9R] folded products. Samples were applied to a Calesil ODS-100 C18 
column (4.6 × 250 mm) and eluted with a 25 min linear gradient of 5-60% acetonitrile (0.1% 





Figure 2. Analgesic activity of Vc1.1[N9R] in PNL and CCI rats. PNL rats (A) and CCI rats 
(B) (n = 8) were treated intramuscularly (i.m.) with saline, Vc1.1 (0.3, 1.5 and 15 nmol/kg) or 
Vc1.1[N9R] (0.3, 1.5 and 15 nmol/kg). The bar graph shows the mean pain threshold 
elevation percentage 2-2.5 h following i.m. injection. Data are expressed as mean ± SD.* p < 




Figure 3. Analgesic activity of benzoyl-Vc1.1[N9R] in PNL and CCI rats. PNL rats (A) 
and CCI rats (B) (n=8) were treated intramuscularly with saline, Vc1.1 (0.3, 1.5 and 15 
 3 
nmol/kg) or benzoyl-Vc1.1[N9R] (0.3, 1.5 and 15 nmol/kg). The bar graph shows the mean 
pain threshold elevation percentage 2-2.5 h following i.m. injection. Data are expressed as 
mean ± SD. * p < 0.05 compared with Vc1.1 group. 
 
 
Figure 4. Effects of the key residues on the potency of Vc.1 at rat α9α10 nAChR. (A) The 
concentration-response relationship for inhibition of α9α10 nAChR by Vc1.1, Vc1.1[N9R] 
and benzoyl-Vc1.1[N9R] (n = 4-6); (B) The concentration-response relationship for 
inhibition of α9α10 by other Vc1.1 variants (n = 4-6). Peptides were applied by perfusion to 
oocytes expressing nAChRs as described in Materials and Methods. The error bars denote the 
SEM of the mean determined from four to six oocytes for each determination. The IC50 




Figure 5. α-Conotoxin Vc1.1 variants, Vc1.1[N9R] and benzoyl-Vc1.1[N9R], inhibit 
CaV2.2 channels by activating GABABRs in HEK293T cells. (A) Representative 
superimposed current traces from HEK293T cells co-expressing human GABABR and 
CaV2.2 channels in the absence and presence of benzoyl-Vc1.1[N9R] (1 nM) and baclofen 
(10 µM). (B)  GABABRs-coupled CaV2.2 inhibition of peak current amplitude by 
benzoyl-Vc1.1[N9R] (1 nM) and baclofen (10 µM) plotted as a function of time. (C) 
Representative time course of inhibition of peak current amplitude in the presence of 
benzoyl-Vc1.1[N9R] (1 nM), followed by application of the selective GABAB receptor 
antagonist, CGP55845 (1 µM). (D) Benzoyl-Vc1.1[N9R] exhibits no effect in the presence 
 5 
of 1 µM CGP55845. (E) Bar graph of inhibition of peak Ba2+ current amplitude by 1 nM 
Vc1.1 (18.8 ± 4.1%), 1 nM Vc1.1[N9R] (19.6 ± 10.8%), 1 nM benzoyl-Vc1.1[N9R] 
(39.7  ± 9.4%), 10 µM baclofen (64.9 ± 5.1%), 10 µM GABA (75.3 ± 6.7%) in 
HEK203T cells co-expressing GABABR and CaV2.2 , 1 nM benzoyl-Vc1.1[N9R] plus 10 
µM baclofen (67.4 ± 5.9%), and the effect of 10 µM benzoyl-Vc1.1[N9R] on CaV2.2 
expressed alone (2.2 ± 2.1%). Data represent mean ± SEM (n = 4-6). *p < 0.05, **p < 
0.01 versus Vc1.1, one-way analysis of variance. (F), (G) and (H) Concentration-response 
relationship for peptide inhibition of peak Ba2+ current in HEK293T cells co-expressing 
GABABR and CaV2.2 channels. Data points represent averaged peak IBa amplitudes 
(I/Icontrol ± SEM); IC50 values obtained for Vc1.1 = 2.4 (0.8~7.0) nM, Vc1.1[N9R] = 4.9 
(2.6~9.1) nM, and benzoyl-Vc1.1[N9R] = 0.2 (0.1~0.3) nM (n = 6–7 cells per data point). 
Numbers in parentheses indicate 95% confidence intervals, n = 4-6. 
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Methods
Electrophysiological recording of TTX-S and TTX-R Na+ currents in rat DRG 
neurons. Whole-cell voltage clamp recordings of voltage-gated sodium currents were 
made in rat DRG neurons which were acutely dissociated from 30-day old 
Sprague–Dawley rats and maintained in short-term primary culture according to the 
method described previously1. All methods and experimental protocols were approved 
and carried out in accordance with the guidelines and regulations of the Beijing Institutes 
for Biological Sciences Animal Research Advisory Committee. DRG neurons of large 
diameter (>35 µm) and those of relatively small diameter (<20 µm) were chosen for 
recording tetrodotoxin-sensitive (TTX-S) and tetrodotoxin-resistant (TTX-R) Na+ 
currents, respectively. TTX (final concentration at 200 nM) was used to isolate TTX-R 
Na+ currents from TTX-S Na+ currents. Electrophysiological patch clamp recording was 
performed as described previously2. TTX-S and TTX-R Na+ currents were evoked by a 
50 ms depolarizing step to 10 mV and +10 mV, respectively, from a holding potential of 
80 mV. 
Oocyte two-electrode voltage clamp recording and data analysis of human α9α10 
subtype. cRNA preparation, oocyte preparation and microinjection of human α9α10 
nAChR were performed as described previously.3 All procedures were approved by the 
University of Sydney Animal Ethics Committee. 
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Electrophysiological recordings were carried out 2–5 days post cRNA microinjection. 
Two-electrode voltage clamp recordings of Xenopus. laevis oocytes expressing human 
nAChRs were performed at room temperature (21−24 °C) using a GeneClamp 500B 
amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale, CA, USA) at a 
holding potential ─80 mV. Voltage-recording and current-injecting electrodes were 
pulled from GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston, MA) and 
filled with 3 M KCl, giving resistances of 0.3–1 MΩ.
Oocytes were incubated in 100 µM BAPTA-AM ~3 h before recording and perfused 
with ND115 solution containing (in mM): 115 NaCl, 2.5 KCl, 1.8 CaCl2, and 10 HEPES 
at pH 7.4 using a continuous Legato 270 push/pull syringe pump perfusion system (KD 
Scientific, Holliston, MA, USA) at a rate of 2 mL/min in an OPC-1 perfusion chamber of 
< 20 µL volume (Automate Scientific, Berkeley, CA, USA). Due to the Ca2+ permeability 
of hα9α10 nAChRs, BAPTA-AM incubation was carried out to prevent the activation of 
X. laevis oocyte endogenous Ca2+-activated chloride channels.
Initially, oocytes were briefly washed with ND115 solution followed by 3 applications 
of acetylcholine (ACh) at half-maximal effective concentration (EC50) of ACh (6 M) for 
human α9α10 nAChRs. Washout with bath solution was done for 3 min between ACh 
applications. Oocytes were incubated with peptides for 5 min with the perfusion system 
turned off, followed by co-application of ACh and peptide with flowing bath solution. All 
peptide solutions were prepared in ND115 + 0.1 % bovine serum albumin. Peak current 
amplitudes before (ACh alone) and after (ACh + peptide) peptide incubation were 
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measured using Clampfit version 10.7.0.3 software (Molecular Devices, Sunnyvale, CA, 
USA), where the ratio of ACh + peptide-evoked current amplitude to ACh alone-evoked 
current amplitude was used to assess the activity of the peptides at human α9α10 nAChRs. 
All electrophysiological data were pooled (n = 5-10) and represent means ± standard 
error of the mean (SEM). Data analysis was performed using GraphPad Prism 7 
(GraphPad Software, La Jolla, CA, USA). The IC50 was determined from 
concentration-response relationships fitted to a non-linear regression function and 
reported with 95% confidence intervals. 
Figure S1. Analgesic activity of Vc1.1 variants at position 9 and 11 in PNL rats. PNL 
rats (n = 8/group) were treated intramuscularly (i.m.) with saline, Vc1.1, Vc1.1 
[N9R,D11R], Vc1.1[N9R], Vc1.1[N9R,D11N] or Vc1.1[N9R,D11S].  The dose of 
peptide was 15 nmol/kg for all treatments. The bar graph shows the mean (SD) pain 
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threshold elevation percentage 2-2.5 h following i.m. injection. *p < 0.05 compared 
with Vc1.1 group.
Figure S2. Analgesic activity of N-terminal modified Vc1.1[N9R] variants in PNL rats. 
PNL rats were treated intramuscularly with saline, Vc1.1, Ac-Vc1.1[N9R], or 
Des-Gly-Vc1.1[N9R] at 15 nmol/kg. The bar graph shows the mean ± SD pain threshold 
elevation percentage 2-2.5 h following i.m. injection of saline, Vc1.1, Ac-Vc1.1[N9R], 
and Des-Gly-Vc1.1[N9R]. p > 0.05 compared with Vc1.1 group.
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Figure S3. Concentrationresponse relationship for inhibition of human α9α10 nAChR 
by Vc1.1[N9R], benzoyl-Vc1.1 and benzoyl-Vc1.1[N9R]. The error bars denote the SEM 
of the mean determined from five to ten oocytes. The IC50 values obtained at the human 
α9α10 subtype are summarized in Table 1. 
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Figure S4. Vc1.1[N9R] inhibition of rat neuronal nAChR subtypes. Vc1.1[N9R] (10 
µM) was applied by perfusion to oocytes expressing nAChRs as described in 
Experimental section. The error bars denote the SEM of the data from four to seven 
oocytes for each determination (n = 3-5). 
Figure S5. Benzoyl-Vc1.1[N9R] inhibition of rat nAChR subtypes. 
Benzoyl-Vc1.1[N9R] (10 µM) was applied by perfusion to oocytes expressing nAChRs 
as described in Experimental section. The error bars denote the SEM of the data from 
four to seven oocytes for each determination (n = 3-5). 
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Figure S6. Effect of Vc1. 1, Vc1.1[N9R] and benzoyl-Vc1.1[N9R] (10 μM) on TTX-R 
Na+ currents in rat DRG neurons (n = 4-6 for each). Superimposed TTX-R Na+ currents 
were evoked by step depolarization (50 ms) to +10 mV from a holding potential of 80 
mV in the absence (control) and presence of 10 µM Vc1.1 (A), 10 μM Vc1.1[N9R] (B), 
or 10 µM benzoyl-Vc1.1[N9R] (C). 
Figure S7. Effect of Vc1. 1, Vc1.1[N9R] and benzoyl-Vc1.1[N9R] (10 μM) on TTX-S 
Na+ currents in rat DRG neurons (n = 4-6 for each). Superimposed TTX-S Na+ currents 
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were evoked by step depolarization (50 ms) to 10 mV from a holding potential of 80 
mV in the absence (control) and presence of 10 μM Vc1.1[N9R], 10 µM 
benzoyl-Vc1.1[N9R] (A) or 10 µM Vc1.1 (B). 
Figure S8. HPLC analysis of (a) linear, (b) folded, and (c) purified products of Vc1.1 
(Purity: 99.8%). Samples were applied to a Agilent Eclipse Plus C18 (5 μm, 4.6 mm×250 
mm) and eluted with a linear gradient of 5-10% B for 0-1 min; 10~50% B (B is 
acetonitrile containing 0.1% TFA) for 1-25 min. Absorbance was monitored at 214 nm. 
Flow rate was 1.0 ml/min. a. linear Vc1.1; b. Vc1.1 folding products; c. Purified Vc1.1. 
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Figure S9. HPLC analysis of (a) linear, (b) folded, and (c) purified products of 
Vc1.1[N9R] (Purity: 98.0%). Analytical conditions were the same as those described in 
Figure S8.
Figure S10. HPLC analysis of (a) linear, (b) folded, and (c) purified products of 
Vc1.1[N9R,D11N] (Purity: 96.9%). Analytical conditions were the same as those 
described in Figure S8.
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Figure S11. HPLC analysis of (a) linear, (b) folded, and (c) purified products of 
Vc1.1[N9R,D11R] (Purity: 95.0%). Analytical conditions were the same as those 
described in Figure S8.
Figure S12. HPLC analysis of (a) linear, (b) folded, and (c) purified products of 
Vc1.1[N9R,D11S] (Purity: 97.8%). Analytical conditions were the same as those 
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described in Figure S8.
Figure S13. HPLC analysis of (a) linear, (b) folded, and (c) purified products of 
DesG-Vc1.1[N9R] (Purity: 100%). Analytical conditions were the same as those 
described in Figure S8.
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Figure S14. HPLC analysis of (a) linear, (b) folded, and (c) purified products of 
Ac-Vc1.1[N9R] (Purity: 96.5%). Analytical conditions were the same as those described 
in Figure S8.
Figure S15. HPLC analysis of (a) linear, (b) folded, and (c) purified products of 
Benzoyl-Vc1.1[N9R] (Purity:97.6%). Analytical conditions were the same as those 
described in Figure S8.
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Figure S16. HPLC analysis of (a) linear, (b) folded, and (c) purified products of 
Benzoyl-Vc1.1(Purity: 95.2%). Analytical conditions were the same as those described in 
Figure S8.
Figure S17. Mass spectrometry of Vc1.1
Vc1.1
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Figure S19. Mass spectrometry of Vc1.1[N9R,D11N]             




Figure S21. Mass spectrometry of Vc1.1[N9R,D11S]                  
Figure S22. Mass spectrometry of DesG-Vc1.1[N9R]  
desG-Vc1.1[N9R]
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Figure S24. Mass spectrometry of benzoyl-Vc1.1[N9R] 
Figure S25. Mass spectrometry of benzoyl-Vc1.1
Benzoyl-Vc1.1
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Figure S26. CD spectrum of Vc1.1   






















Figure S27. CD spectrum of Vc1.1[N9R]      
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Figure S28. CD spectrum of Vc1.1[N9R,D11N]        





















Figure S29. CD spectrum of Vc1.1[N9R,D11R]         
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Figure S30. CD spectrum of Vc1.1[N9R,D11S]       




















Figure S31. CD spectrum of DesG-Vc1.1[N9R]        
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Figure S32. CD spectrum of Ac-Vc1.1[N9R]    
























Figure S33. CD spectrum of benzoyl-Vc1.1[N9R]    
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Figure S34. CD spectrum of benzoyl-Vc1.1    
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